Target
CXCR1
3 abstracts
Abstract
Safety and efficacy of first-in-class CXCR1/2 inhibitor SX-682 in combination with pembrolizumab (pem) in patients (pts) with metastatic melanoma (mMEL) with disease progression on anti–PD-1 therapy.Org: Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Mayo Clinic, Rochester, MN, USA, University of Rochester, Rochester, NY, Massachusetts General Hospital, Marblehead, MA, Dana-Farber Cancer Institute, Boston, MA, USA,
Abstract
Comprehensive characterization of androgen receptor expression in breast cancer.Org: Caris Life Sciences, Irving, TX, City of Hope National Medical Center, Washington University School of Medicine in St Louis, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI,
Abstract
Correlation of cancer testis antigen and interleukin expression with survival in small bowel neuroendocrine tumors.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Houston, TX, MD Anderson Cancer Center, University of Texas MD Anderson Cancer Center,